How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

731 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. (PubMed)

(in men only). Meta-analysis of three studies showed a robust effect of metformin in reducing body mass index and waist circumference but no effects on blood glucose, triglyceride levels, or HDL levels. In addition, there is limited evidence for combined calorie restriction and exercise as a non-pharmacological alternative for the treatment of clozapine-induced obesity, but only in an in-patient setting. Rosiglitazone, topiramate, sibutramine, phenylpropanolamine, modafinil, and atomoxetine have

Full Text available with Trip Pro

2016 European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

143. Management of diabetes

participants with type 2 diabetes, hypertension, MI, asthma and breast cancer. Four RCTs provided data comparing a Protein Sparing Modified Fast (PSMF) with a Low Calorie Diet (LCD) and found no statistically significant differences in HbA1c or weight loss between these two interventions. 107 A systematic review, including 22 studies on pharmacotherapy for weight loss in adults with type 2 diabetes, focused mainly on weight loss and HbA1c data for orlistat (n=2,036 participants), sibutramine (n=296 (...) ) and fluoxetine (n=1,047). 108 Orlistat resulted in a mean pooled effect weight loss of 2.0 kg (95% CI 1.3 to 2.8) associated with a reduction in HbA1c of 0.5% (5.46 mmol/mol) (95% CI 0.3 (3.28) to 0.6 (6.56)) with follow up between 24 and 57 weeks. Sibutramine resulted in mean pooled effect weight loss of 5.1 kg (95% CI 3.2 to 7.0) with no reduction in HbA1c after follow up of 12 to 52 weeks. Fluoxetine resulted in mean pooled effect weight loss of 3.4 kg (95% CI, 1.7 to 5.2) at 8 to 16 weeks, 5.1 kg (95% CI

2010 SIGN

144. Long-term randomized clinical trials of pharmacological treatment of obesity: systematic review

search terms were reported. Study selection Randomised controlled trials that evaluated the efficacy of treatments with orlistat, sibutramine and rimonabant, that followed participants for at least 24 months and that measured weight loss were eligible for inclusion. Participants with hypertension (sibutramine studies) and neuro-psychiatric diseases (rimonabant studies) were excluded. Most studies included clinically obese white women (without cardiac, renal, liver and gastrointestinal illnesses (...) to intervention. Results of the review Eleven RCTs (n=11,710, range 61 to 3,305 participants) met the inclusion criteria. Seven studies assessed orlistat and two studies each assessed sibutramine and rimonabant. One study scored 5, three studies scored 4, five studies scored 3 and one study scored 2 on the Jadad scale (score for one study not reported). Eight studies were double blind. Nine studies were analysed by intention to treat (ITT). Baseline differences were reported to be significant. Withdrawal

2010 DARE.

145. Weight-reducing drugs may be beneficial in hypertensive patients

Weight-reducing drugs may be beneficial in hypertensive patients PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Weight-reducing drugs may be beneficial in hypertensive patients Clinical question How effective are weight-reducing drugs in hypertensive patients? Bottom line Although trials of orlistat and sibutramine in patients with elevated blood pressure demonstrated statistically (...) significant decreases in weight, orlistat reduced blood pressure and sibutramine increased blood pressure. Caveat No long term mortality and morbidity RCT evidence is available for these drugs. Trials of rimonabant in this patient population could not be included. Context Orlistat, sibutramine and rimonabant are the main anti- obesity drugs in current use. Orlistat and sibutramine have been approved for long term treatment of obesity throughout much of the world. Rimonabant was approved for use

2011 Cochrane PEARLS

146. Finally, the Department of Justice and FDA go after unsafe supplements in a big way

manufacturing practices regulations. Truly, this was an example of . Oh, and Bethel also made medical claims that some of their supplements were able to cure, mitigate, treat, or prevent diseases. It turns out that some of the products marketed as dietary supplements by Bethel contained—you guessed it!—real drugs. These included sibutramine, the active ingredient of Meridia, a drug approved in 1997 to treat obesity that was removed from the market in 2010 because of the risk of serious adverse events

2015 Respectful Insolence

147. Interventions for treating obesity in children. (PubMed)

and sibutramine) were found in 10 studies. No surgical intervention was eligible for inclusion. The studies included varied greatly in intervention design, outcome measurements and methodological quality.Meta-analyses indicated a reduction in overweight at 6 and 12 months follow up in: i) lifestyle interventions involving children; and ii) lifestyle interventions in adolescents with or without the addition of orlistat or sibutramine. A range of adverse effects was noted in drug RCTs.While there is limited (...) quality data to recommend one treatment program to be favoured over another, this review shows that combined behavioural lifestyle interventions compared to standard care or self-help can produce a significant and clinically meaningful reduction in overweight in children and adolescents. In obese adolescents, consideration should be given to the use of either orlistat or sibutramine, as an adjunct to lifestyle interventions, although this approach needs to be carefully weighed up against the potential

Full Text available with Trip Pro

2009 Cochrane

148. Overweight and obesity - use of portion control in management

in management clinical protein in the diet, and • checking that the major carbohydrate sources in the diet have a low glycaemic index (thus supplying a source of energy over a longer period and reducing fluctuations in both blood glucose and insulin concentrations). Pharmacotherapy may assist with appetite control. A Cochrane review found that taking sibutramine resulted in weight loss 4.2 kg greater than the placebo. 34 While appetite suppressant medications may assist with weight loss, they are more

2010 Clinical Practice Guidelines Portal

149. What weight loss treatment options do geriatric patients with overweight and obesity want to consider? (PubMed)

What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Since the 1990s, a number of weight loss medications have been removed from the USA and or European market because of adverse events associated with these medications. These medications include fenfluramine (heart valve thickening), sibutramine (cardiovascular risk) and rimonabant (depression). This history may affect a patient's desire to consider weight loss medications as an option

Full Text available with Trip Pro

2016 Obesity science & practice

150. Lack of evidence to choose second line drug treatments for type 2 diabetes

glycaemic control. This systematic review set out to find out which is the most effective choice. The reviewers conducted a search of the main bibliographic databases and found 49 randomised trials relevant to the topic. These studies evaluated the effectiveness of sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogues, insulins and insulin analogues, alpha-glucosidase inhibitors and the weight-loss agents orlistat and sibutramine. The reviewers analysed combination

2011 The Diabetes Elf

151. Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin

release), psyllium preparation such as Metamucil (>2 tablespoons/day), fibrates and derivatives, bile cholesterol absorption inhibitors including ezetimibe; Any supplement containing plan sterols/stanols (i.e. Benecol, beta‐sitosterol, Cholestatin, Phytoquest, Take Control) or cholestin (i.e. Chinese red yeast, fermented on rice; Hong Qu, Hong Chu, Herbvalin, Ruby Monascus, Monascus purpureus rice); Neomycin (oral); Adrenocortical steroids* Sibutramine (Meridia); Insulin; Orlistat (Xenical

2015 Clinical Trials

152. Health Beneficial Effects of Krill Oil and Lean and Fatty Fish

1.3-4.0 mmol/L Willingness to eat fish Willingness to not take omega-3 or other dietary supplements during the study. Exclusion Criteria: Pregnancy or lactation Any chronic disease, including diabetes type 1 or 2. CVD or cancer past 6 months Elevated thyroid hormones or TSH levels Elevated total cholesterol (>7.8 mmol/L) or fasting triglycerides (>4.0 mmol/L) Use of prescription drugs that may affect triglycerides (e.g. diabetes drugs, Cyclosporin A, Orlistat and Sibutramine), except statins

2015 Clinical Trials

153. SATIN: Satiety Innovation. Study 2- University of Aberdeen

obstruction. Psychiatric disorder: severe depression, bulimia, anorexia, schizophrenia, bipolar disorder. Gastrointestinal procedure or surgery in the past three months. Disorders of swallowing, severe dysphagia to food or pills. Pregnancy Medication exclusion criteria Appetite modulator drugs: orlistat, sibutramine, rimonabant. Mood disorder medications: antidepressants, lithium. Others: oral antidiabetics, insulin, digoxin, thyroid hormones, antibiotics, steroids or immunosuppressants, recreational

2015 Clinical Trials

154. Domperidone for Chronic Nausea and Vomiting

, norepinephrine, ondansetron, oxytocin, paliperidone, perflutren lipid microspheres, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine, ritodrine, roxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus, telithromycin, terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib, vardenafil, voriconazole. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2015 Clinical Trials

155. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. (PubMed)

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in pulse rate, and the impact (...) of these changes on subsequent cardiovascular outcome events in both the placebo and sibutramine groups.9804 males and females, aged ⩾55 years, with a body mass index of 27-45 kg m(-)(2) were included in this current subanalysis of the SCOUT trial. Subjects were required to have a history of cardiovascular disease and/or type 2 diabetes mellitus with at least one cardiovascular risk factor, to assess cardiovascular outcomes. The primary outcome event (POE) was a composite of nonfatal myocardial infarction

2015 International Journal of Obesity

156. Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response. (PubMed)

Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response. We examined rapid response among obese patients with binge-eating disorder (BED) in a randomized clinical trial testing antiobesity medication and self-help cognitive-behavioral therapy (shCBT), alone and in combination, in primary-care settings.One hundred four obese patients with BED were randomly assigned to 1 of 4 treatments: sibutramine (...) , placebo, shCBT + sibutramine, or shCBT + placebo. Treatments were delivered by generalist primary-care physicians and the medications were given double-blind. Independent assessments were performed by trained and monitored doctoral research clinicians monthly throughout treatment, posttreatment (4 months), and at 6- and 12-month follow-ups (i.e., 16 months after randomization). Rapid response, defined as ≥65% reduction in binge eating by the fourth treatment week, was used to predict outcomes.Rapid

Full Text available with Trip Pro

2015 Journal of Consulting and Clinical Psychology

158. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

of 14 calendar days known to affect weight or glucose metabolism, such as weight loss/modifying (e.g.; sibutramine, orlistat, thyroid hormones, corticosteroids) Impaired liver function, defined as alanine aminotransferase (ALT) at least 2.5 times upper limit of normal Renal impairment eGFR (electronic case report form) below 60 mL/min/1.73 m^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Screening calcitonin at least 50 ng/L History of pancreatitis (acute or chronic) Personal

2015 Clinical Trials

159. Correction to Grilo et al. (2015). (PubMed)

article appeared in record 2015-02674-001.)We examined rapid response among obese patients with binge-eating disorder (BED) in a randomized clinical trial testing antiobesity medication and self-help cognitive-behavioral therapy (shCBT), alone and in combination, in primary-care settings.One hundred four obese patients with BED were randomly assigned to 1 of 4 treatments: sibutramine, placebo, shCBT + sibutramine, or shCBT + placebo. Treatments were delivered by generalist primary-care physicians

2015 Journal of Consulting and Clinical Psychology

160. EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects

to affect GI motility, prescription or over the counter weight loss medications such as Sibutramine hydrochloride monohydrate and Orlistat Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all equivalent antibiotics Any characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement in this clinical trial Previous GI surgery that could affect the ability to place the liner or the function of the implant. Subjects unable

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>